Effects of antimuscarinics on voiding function after cerebral infarction in a rat model of overactive bladder

European Journal of Pharmacology

Volumn 577, Issue 1-3, 2007, Pages 143-149

  Yusup, Anwar ^a   Akino, Hironobu ^a   Miwa, Yoshiji ^a   Oyama, Nobuyuki ^a   Aoki, Yoshitaka ^a   Ito, Hideaki ^a   Tanase, Kazuya ^a   Matsuta, Yosuke ^a   Nakai, Masaharu ^a   Yokoyama, Osamu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

(Rat); Cerebral infarction; Micturition; Muscarinic; Overactive bladder; Tolterodine

Indexed keywords

ATROPINE; MUSCARINIC RECEPTOR BLOCKING AGENT; TOLTERODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CAPACITY; BLADDER CONTRACTION; BLOOD BRAIN BARRIER; BRAIN INFARCTION; CONTROLLED STUDY; CYSTOMETRY; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG EFFECT; FEMALE; MICTURITION; NONHUMAN; OCCLUSIVE CEREBROVASCULAR DISEASE; OVERACTIVE BLADDER; PRIORITY JOURNAL;

ANIMALS; ATROPINE; BENZHYDRYL COMPOUNDS; CRESOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; INFARCTION, MIDDLE CEREBRAL ARTERY; INJECTIONS, INTRAVENTRICULAR; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PHENYLPROPANOLAMINE; RATS; RATS, SPRAGUE-DAWLEY; URINARY BLADDER; URINARY BLADDER, OVERACTIVE; URINARY CATHETERIZATION; URINATION;

EID: 35448932052     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.08.032     Document Type: Article

References (33)

1. Abbott N.J., Ronnback L., and Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7 (2006) 41-53
2. Abrams P., Cardozo L., Fall M., Griffiths D., Rosier P., Ulmsten U., Van Kerrebroeck P., Victor A., and Wein A. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 61 (2003) 37-49
3. Abrams P., Andersson K.E., Buccafusco J.J., Chapple C., de Groat W.C., Fryer A.D., Kay G., Laties A., Nathanson N.M., Pasricha P.J., and Wein A.J. Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br. J. Pharmacol. 148 (2006) 565-578
4. Abrams P., Kaplan S.A., De Koning Gans H.J., and Millard R. Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J. Urol. 175 (2006) 999-1004
5. Andersson K.-E. Antimuscarinics for the treatment of overactive bladder. Lancet Neurol. 3 (2004) 46-53
6. Aquilonius S.M., Lundholm B., and Windbladh B. Effects of some anticholinergic drugs on cortical acetylcholine release and motor activity in rats. Eur. J. Clin. Pharmacol. 20 (1972) 224-230
7. Braverman A.S., and Ruggieri Sr. M.R. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285 (2003) R701-R708
8. Comford E.M., and Hyman S. Blood-brain barrier permeability to small and large molecules. Adv. Drug Deliv. Rev. 36 (1999) 145-163
9. de Groat W.C. Integrative control of the lower urinary tract: preclinical perspective. Br. J. Pharmacol. 147 Suppl 2 (2006) S25-S40
10. Fetscher C., Fleichman M., Schmidt M., Krege S., and Michel M.C. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br. J. Pharmacol. 136 (2002) 641-643
11. Finney S.M., Andersson K.E., Gillespie J.I., and Stewart L.H. Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions?. B.J.U. Int. 98 (2006) 503-507
12. Habgood M.D., Begley D.J., and Abbott N.J. Determinants of passive drug entry into the central nervous system. Cell. Mol. Neurobiol. 20 (2000) 231-253
13. Ishizuka O., Gu B.J., Yang Z.X., Nishizawa O., and Andersson K.E. Functional role of central muscarinic receptors for micturition in normal conscious rats. J. Urol. 168 (2002) 2258-2262
14. Kataoka K., Hayakawa T., Kuroda R., Yuguchi T., and Yamada K. Cholinergic deafferentation after focal cerebral infarct in rats. Stroke 22 (1991) 1291-1296
15. Matsui M., Motomura D., Karasawa H., Fujikawa T., Jiang J., Komiya Y., Takahashi S., and Taketo M.M. Multiple functional defects in peripheral autonomic organs in mice lacking muscarinic acetylcholine receptor gene for the M3 subtype. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 9579-9584
16. Matsui M., Motomura D., Fujikawa T., Jiang J., Takahashi S., Manabe T., and Taketo M.M. Mice lacking M2 and M3 muscarinic acetylcholine receptors are devoid of cholinergic smooth muscle contractions but still viable. J. Neurosci. 22 (2002) 10627-10632
17. Milsom I., Abrams P., Cardozo L., Roberts R.G., Thuroff J., and Wein A.J. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. B.J.U. Int. 87 (2001) 760-766
18. Nakai M., Akino H., Kaneda T., Matsuta Y., Shiyama R., Tanase K., Ito H., Aoki Y., Oyama N., Miwa Y., and Yokoyama O. Acetylcholinesterase inhibitor acting on the brain improves detrusor overactivity caused by cerebral infarction in rats. Neuroscience 142 (2006) 475-480
19. Nilvebrant L. The mechanism of action of tolterodine. Rev. Contemp. Pharmacother 11 (2000) 13-27
20. Nitti V.W., Dmochowski R., Appell R.A., Wang J.T., Bavendam T., and Guan Z. Efficacy and tolerability of tolterodine extended-release in continent patients with overactive bladder and nocturia. B.J.U. Int. 97 (2006) 1262-1266
21. Paxinos G., and Watson C. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Orlando, FL
22. Pontari M.A., Braverman A.S., and Ruggieri Sr. M.R. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am. J. Physiol. Regul. Integr. Comp. Physiol. 286 (2004) R874-R880
23. Roehrborn C.G., Abrams P., Rovner E.S., Kaplan S.A., Herschorn S., and Guan Z. Efficacy and tolerability of tolterodine extended-release in men with overactive bladder and urgency urinary incontinence. B.J.U. Int. 97 (2006) 1003-1006
24. Sanchez C., and Meier E. Central and peripheral mediation of hypothermia, tremor, and salivation induced by muscarinic agonists in mice. Pharmacol. Toxicol. 72 (1993) 262-267
25. Stewart W.F., Van Rooyen J.B., Cundiff G.W., Abrams P., Herzog A.R., Corey R., Hunt T.L., and Wein A.J. Prevalence and burden of overactive bladder in the United States. World J. Urol. 20 (2003) 327-336
26. Sugaya K., Matsuyama K., Takakusaki K., and Mori S. Electrical and chemical stimulations of the pontine micturition center. Neurosci. Lett. 80 (1987) 197-201
27. Todorova A., Vonderheid-Guth B., and Dimpfel W. Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system. J. Clin. Pharmacol. 41 (2001) 636-644
28. van Kerrebroeck P., Kreder K., Jonas U., Zinner N., and Wein A. Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder. Urology 57 (2001) 414-421
29. Yokoyama O., Ootsuka N., Komatsu K., Kodama K., Yotsuyanagi S., Niikura S., Nagasaka Y., Nakada Y., Kanie S., and Namiki M. Forebrain muscarinic control of micturition reflex in rats. Neuropharmacology 41 (2001) 629-638
30. Yokoyama O., Yoshiyama M., Namiki M., and de Groat W.C. Role of the forebrain in bladder overactivity following cerebral infarction in the rat. Exp. Neurol. 163 (2000) 469-476
31. Yokoyama O., Yusup A., Miwa Y., Oyama N., Aoki Y., and Akino H. Effects of tolterodine on an overactive bladder depend on suppression of C-fiber bladder afferent activity in rats. J. Urol. 174 (2005) 2032-2036
32. Yotsuyanagi S., Yokoyama O., Komatsu K., Kodama K., Nagasaka Y., and Namiki M. Role of cyclooxygenase-2 in the development of bladder overactivity after cerebral infarction in the rat. J. Urol. 174 (2005) 365-369
33. Yotsuyanagi S., Narimoto K., and Namiki M. Mild brain ischemia produces bladder hyperactivity without brain damage in rats. Urol. Int. 77 (2006) 57-63